Herrmann, Christina <br/><br/>
Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer.  [electronic resource] 

 -  Oncology  2007 
 - 335-9 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1423-0232 
<br/><br/><label>Standard No.: </label>10.1159/000134477  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Capecitabine<br/>Cohort Studies<br/>Deoxycytidine--administration & dosage<br/>Disease Progression<br/>Drug Administration Schedule<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Male<br/>Middle Aged<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin<br/>Palliative Care<br/>Pancreatic Neoplasms--drug therapy<br/>Prognosis<br/>Survival Rate<br/>Time Factors<br/>Gemcitabine